Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm

被引:8
|
作者
Nishino, Mizuki [1 ,2 ]
Wakai, Satoshi [3 ]
Hida, Tomoyuki [1 ,2 ]
Dahlberg, Suzanne E. [4 ]
Ozaki, Masahiro [3 ]
Hatabu, Hiroto [1 ,2 ]
Tachizaki, Hisashi [3 ]
Johnson, Bruce E. [5 ,6 ,7 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[3] Canon Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan
[4] Dana Farber Canc Inst, Dept Biostat, 450 Brookline Ave, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Dept Med, 450 Brookline Ave, Boston, MA 02215 USA
[7] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
Lung cancer; Epidermal growth factor receptor; EGFR inhibitor; Computed tomography; Tumor growth rate; DIFFERENT TREATMENT MODALITIES; RESPONSE EVALUATION CRITERIA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; NSCLC PATIENTS; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; PROGRESSION;
D O I
10.1016/j.ejrad.2018.10.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors. Materials and methods: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists. Results: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of <= 0.15/month had a perfect interobserver agreement (kappa = 1.00), and an excellent intraobserver agreement (kappa = 0.895). Conclusions: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [21] Volumetric Tumor Growth in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutations During EGFR-Tyrosine Kinase Inhibitor Therapy Developing Criteria to Continue Therapy Beyond RECIST Progression
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Cardarella, Stephanie
    Jackman, David M.
    Rabin, Michael S.
    Ramaiya, Nikhil H.
    Hatabu, Hiroto
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CANCER, 2013, 119 (21) : 3761 - 3768
  • [22] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [23] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [24] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [25] Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
    Fan, Y.
    Yu, X.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2228
  • [26] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
    Pao, William
    Chmielecki, Juliann
    NATURE REVIEWS CANCER, 2010, 10 (11) : 760 - 774
  • [27] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [28] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
  • [29] Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer-ready for prime time?
    Arulananda, Surein
    John, Thomas
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 1728 - 1731
  • [30] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
    Zhang, Shi-Ling
    Zhang, Chan -Yuan
    Chen, Yu-Qing
    Li, Yu -Fa
    Xie, Zhi
    Zhang, Xu-Chao
    Zhou, Qing
    Zhong, Wen-Zhao
    Huang, Jie
    Sun, Hao
    Zheng, Ming-Ying
    Xiao, Fa-Man
    Yan, Hong-Hong
    Lu, Dan-Xia
    Lv, Zhi-Yi
    Wu, Yi-Long
    Chen, Hua-Jun
    Yang, Jin-Ji
    JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635